EBF2 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population disrupting the EBF2 gene in the near-haploid HAP1 cell line. This knockout model enables investigation of EBF2-dependent transcriptional networks and differentiation processes without clonal bias. The polyclonal format captures a range of loss-of-function phenotypes, making it suitable for population-scale functional genomics, pathway analysis, and drug target validation.
The HAP1 cell line is a near-haploid human cell model derived from the KBM-7 chronic myeloid leukemia line. Its fibroblast-like adherent morphology and largely haploid karyotype simplify genetic manipulation, making HAP1 a standard tool for large-scale knockout and chemogenomic screens. Because most chromosomes are present in a single copy (except chromosome 8 and part of 15), gene disruption typically yields a direct observable phenotype without requiring homozygous editing. This feature renders HAP1 ideal for polyclonal knockout pools targeting transcription factors, signaling molecules, and metabolic regulators.
EBF2 encodes a helix-loop-helix transcription factor critical for B-cell lineage specification, neurogenesis, and adipogenesis. It is activated downstream of Notch and IL-7 cytokine signaling and cooperates with the E2A transcription factor to launch the B-cell transcriptional program. EBF2 forms regulatory complexes with EBF1, PAX5, and RUNX1 to drive expression of key B-cell identity genes such as CD79a and PAX5. In adipogenesis, EBF2 directly regulates PPARG in concert with C/EBP??. CRISPR/Cas9-mediated disruption of EBF2 in HAP1 cells impairs transcription of these targets, providing a loss-of-function model to dissect the interplay among lineage-specifying transcription factors and their downstream effectors.
In the HAP1 background, this knockout polyclonal pool offers a genetically defined system to probe the consequences of ablating a pioneer transcription factor on downstream gene networks. Although HAP1 cells are not B-lymphoid, they express components of Notch and cytokine pathways upstream of EBF2 and retain epigenetic plasticity suitable for lineage reprogramming studies. By comparing knockout and wild-type cells, researchers can identify direct EBF2 targets in a non-lymphoid environment, clarifying its contributions to B-cell acute lymphoblastic leukemia, glioma, and metabolic disorders linked to adipogenesis.
This EBF2 knockout model supports functional genomics screening, B-cell developmental biology, leukemia research, and metabolic disease studies. Typical experiments use RT-qPCR for target gene quantification (PAX5, CD79a, PPARG), Western blotting for EBF2 protein loss, and RNA-seq for transcriptome profiling. ChIP-qPCR assesses chromatin occupancy of EBF2 binding partners, while flow cytometry with B-cell markers enables phenotypic analysis. Adipogenic differentiation assays extend the utility to metabolism research. For further information, please contact Ascent Research.
